Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
7 readings, 4 filed under bull and 3 under bear. Every figure is ours; the model chose the side.
the bull case· 4
17
supplier and customer ties disclosed in sec filings
sec filingsedgar345
managers reporting a position in thirteen f filings
13fJun 30 '265
funds on file reporting a position in the company
n-portas of Jun 30 '26+12.88%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 3
7 of 8
recent reports where the move came in under options implied range
earnings historyimplied vs realized4 of 23
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '2619
managers whose positions together make up four fifths of reported value
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 9 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
345 managers report a position worth $1.4B between them, and 19 of them hold 80% of it.
tall tick = annual report · 1 on record
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Prev close 3.24 · gapped above the open, never looked back. High/low 3.30 at 9:30 am ET, 3.25 at 5:30 am ET.
Recursion Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Of the 6 companies Recursion Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
RXRX (Recursion Pharmaceuticals, Inc.) has 12 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: NVDA +1.69%, in semiconductor.